AVBP — ArriVent Biopharma Share Price
0.000.00%
Last trade - 00:00- $724.54m
- $505.68m
- 19
- 25
- 58
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.81 | ||
| Price to Tang. Book | 2.81 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.6% | ||
| Return on Equity | -154.1% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 13.07 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The Company is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 14th, 2021
- Public Since
- January 26th, 2024
- No. of Shareholders
- 59
- No. of Employees
- 52
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 34,016,197
- Address
- 18 Campus Blvd., Suite 100, NEWTOWN SQUARE, 19073-3269
- Web
- https://arrivent.com/
- Phone
- +1 2407806356
- Auditors
- KPMG LLP
Upcoming Events for AVBP
Arrivent Biopharma Inc Annual Shareholders Meeting
Q2 2025 Arrivent Biopharma Inc Earnings Release
Similar to AVBP
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the ArriVent Biopharma share price?
As of Today at 19:20 UTC, shares in ArriVent Biopharma are trading at $21.30. This share price information is delayed by 15 minutes.
How has the ArriVent Biopharma share price performed this year?
Shares in ArriVent Biopharma last closed at $21.30 and the price had moved by +26.79% over the past 365 days. In terms of relative price strength the ArriVent Biopharma share price has outperformed the S&P500 Index by +14.33% over the past year.
What are the analyst and broker recommendations for ArriVent Biopharma?
The overall consensus recommendation for ArriVent Biopharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the ArriVent Biopharma dividend yield?
ArriVent Biopharma does not currently pay a dividend.
Does ArriVent Biopharma pay a dividend?
ArriVent Biopharma does not currently pay a dividend.
When does ArriVent Biopharma next pay dividends?
ArriVent Biopharma does not currently pay a dividend.
How do I buy ArriVent Biopharma shares?
To buy shares in ArriVent Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ArriVent Biopharma?
As of the previous close price of $21.30, shares in ArriVent Biopharma had a market capitalisation of $724.54m.
Where are ArriVent Biopharma shares listed?
Here are the trading details for ArriVent Biopharma:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: AVBP
What kind of share is ArriVent Biopharma?
Based on an overall assessment of its quality, value and momentum ArriVent Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ArriVent Biopharma share price forecast for 2025?
The analyst consensus target price for shares in ArriVent Biopharma is $39.29. That is 84.46% above the last closing price of $21.30.
Analysts covering ArriVent Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$2.93 for the next financial year.
Find out moreWhat is the trend in the ArriVent Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ArriVent Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -30.48%.
As of the last closing price of $21.30, shares in ArriVent Biopharma were trading -14.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ArriVent Biopharma PE Ratio?
The ArriVent Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $21.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ArriVent Biopharma?
We do not have data on ArriVent Biopharma's directors